Published by Auckland, Counties Manukau and Waitematā DHBs on 28/03/2022 3:44:55 PM.

A regional process is now in place for administering Remdesivir at the Greenlane Clinical Centre to patients referred from the community. Remdesivir is an antiviral that reduces the risk of severe COVID-19 disease if given early in the course of the infection. It is given intravenously over 30 to 120 minutes on 3 consecutive days. Information about Remdesivir is available here.

• Patients who may potentially be eligible are unvaccinated or incompletely vaccinated patients over 60 years of age if Maori or Pacifika, or over 70 years if other ethnicities, and with additional comorbidities. Adults of any age/ethnicity who are severely immunocompromised may also be eligible, regardless of vaccination status. See Remdesivir algorithm attached below.
• Full eligibility criteria and further information, including how to make a referral, is available on the COVID-19 Case Management in Adults HealthPathway under COVID-19 Clinical Review > COVID-19 modifying therapy. It is very important that you familiarise yourself with this information before referring.
• All potential referrals for children must be discussed with their usual paediatrician in the first instance. See COVID-19 Case Management in Children.
• Please note that demand may exceed infusion centre capacity or drug supply, so prioritisation will be necessary and some referred patients may not be able to receive Remdesivir, even if they meet the PHARMAC or regional criteria.

Metro Auckland Therapeutics Algorithm V1.1 28-03-2022.pdf [415.5 KB]